Silver Rock Financial’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Silver Rock Financial’s Portfolio PBAXU Stock Details PBAXU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-46,243	Closed	-$467K	–	179
2022 Q3	$467K	Hold	46,243	–	–	0.1%	146
2022 Q2	$465K	Hold	46,243	–	–	0.1%	150
2022 Q1	$465K	Hold	46,243	–	–	0.09%	159
2021 Q4	$463K	Buy	+46,243	New	+$468K	0.08%	165

Other funds holding PBAXU

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Silver Rock Financial's PBAXU Position: Q4 2022 in Review

Silver Rock Financial sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q4 2022, closing a stake of 46,243 shares — an estimated $467K sold.

Silver Rock Financial first reported a position in PBAXU in Q4 2021 and held it in 4 quarters. The position peaked at $467K in Q3 2022. 3 funds tracked by Wall St. Rank hold PBAXU as of Q4 2022.

Silver Rock Financial reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Silver Rock Financial sold 46,243 Phoenix Biotech Acquisition Corp. Unit shares in Q4 2022, an estimated $467K.
Silver Rock Financial first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
Silver Rock Financial's Phoenix Biotech Acquisition Corp. Unit position peaked at $467K in Q3 2022.
3 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q4 2022.

Based on Silver Rock Financial's 13F filing for Q4 2022, filed 14 Feb 2023.